… Nonvitamin K antagonist oral anticoagulants (NOACs), mainly including thrombin inhibitor
(dabigatran etexilate) and blood coagulation factor X inhibitors (rivaroxaban, apixaban, …

… retrieved for dabigatran etexilate, rivaroxaban and apixaban, respectively. … vitamin K
antagonist oral anticoagulants in venous thromboembolism patients: a metaanalysis of real-world …

… OAC主要包括VKAs和非维生素K拮抗剂口服抗凝药物(non-vitamin K antagonist oral … 加群
酯(dabigatran),以及直接凝血因子Xa抑制剂利伐沙班(rivaroxaban),阿哌沙班(apixaban),艾…

… , the use of rivaroxaban is more common, but clinical use of rivaroxaban, rivaroxaban drug
… and extremely high peak concentrations of rivaroxaban. This study presents the current …

… Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular
atrial fibrillation:a retrospective cohort study[J].J Am Heart Assoc, 2015, 4(4):e001798. …

… 与口服维生素K 拮抗剂(vitamin K antagonists,VKAs)华法林相比,利… and edoxaban and the
thrombin inhibitor dabigatran etex… apixaban and rivaroxaban exposure in a real-world setting [J]. …

… Compared with the traditional oral anticoagulant vitamin K antagonist (VKA), DOACs
have similar anticoagulant effect, better safety, easier administration and less intracranial …

… of Ida⁃ rucizumab in a patient with Dabigatran-induced cerebral hemorrhage,and …
Real world data on the concurrent use of p-glycoprotein or cytochrome 3A4 drugs and non-vitamin …

… new oral anticoagulants ( NOACs) rivaroxaban and dabigatran versus warfarin in the treatment
of … Use of non ‐ vitamin K oral anticoagulants in people with atrial fibrillation and diabetes …

… patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational
… Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in …